Thromboxane A2 Synthetase Inhibitor Plus Low Dose Aspirin : Can It Be a Salvage Treatment in Acute Stroke Beyond Thrombolytic Time Window.
Gyu Hwan An, Sook Young Sim, Cheol Su Jwa, Gang Hyeon Kim, Jong Yun Lee, Jae Kyu Kang
J Korean Neurosurg Soc. 2011;50(1):1-5. DOI: https://doi.org/10.3340/jkns.2011.50.1.1
Citations to this article as recorded by 
Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
Chan Zou, Xiaocong Zuo, Jie Huang, Ye Hua, Shuang Yang, Xiaoyan Yang, Can Guo, Hongyi Tan, Jun Chen, Zhaoxing Chu, Qi Pei, Guoping Yang
Frontiers in Pharmacology.2019;[Epub] CrossRef
Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis
Tomoki Wada, Hideo Yasunaga, Hiromasa Horiguchi, Kiyohide Fushimi, Takehiro Matsubara, Susumu Nakajima, Naoki Yahagi
Journal of Stroke and Cerebrovascular Diseases.2016; 25(12): 2828. CrossRef
MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A 2 inhibition
Weirong Fang, Jie Wei, Dan Han, Xi Chen, Guangwei He, Qiang Wu, Shaoxing Chu, Yunman Li
Thrombosis Research.2014; 133(4): 610. CrossRef
N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production
Yi Zhou, Jinru Huang, Wei He, Wenxiang Fan, Weirong Fang, Guangwei He, Qiang Wu, Shaoxing Chu, Yunman Li
Pharmacology Biochemistry and Behavior.2014; 124: 458. CrossRef